Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Oncology Drugs Market, by Indication
1.4.2 Global Oncology Drugs Market, by Drug Class Type
1.4.3 Global Oncology Drugs Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2019, Mar – 2023, Nov) Leading Players
4.4 Porter’s Five Forces Analysis
Chapter 5. Global Oncology Drugs Market by Indication
5.1 Global Breast Cancer Market by Region
5.2 Global Prostate Cancer Market by Region
5.3 Global Lung Cancer Market by Region
5.4 Global Stomach Cancer Market by Region
5.5 Global Colorectal Cancer Market by Region
5.6 Global Liver Cancer Market by Region
5.7 Global Esophagus Cancer Market by Region
5.8 Global Cervical Cancer Market by Region
5.9 Global Kidney Cancer Market by Region
5.10. Global Bladder Cancer Market by Region
5.11 Global Other Cancer Market by Region
Chapter 6. Global Oncology Drugs Market by Drug Class Type
6.1 Global Targeted Therapy Market by Region
6.2 Global Immunotherapy (Biologic Therapy) Market by Region
6.3 Global Chemotherapy Market by Region
6.4 Global Hormonal Therapy Market by Region
Chapter 7. Global Oncology Drugs Market by Region
7.1 North America Oncology Drugs Market
7.1.1 North America Oncology Drugs Market by Indication
7.1.1.1 North America Breast Cancer Market by Country
7.1.1.2 North America Prostate Cancer Market by Country
7.1.1.3 North America Lung Cancer Market by Country
7.1.1.4 North America Stomach Cancer Market by Country
7.1.1.5 North America Colorectal Cancer Market by Country
7.1.1.6 North America Liver Cancer Market by Country
7.1.1.7 North America Esophagus Cancer Market by Country
7.1.1.8 North America Cervical Cancer Market by Country
7.1.1.9 North America Kidney Cancer Market by Country
7.1.1.10 North America Bladder Cancer Market by Country
7.1.1.11 North America Other Cancer Market by Country
7.1.2 North America Oncology Drugs Market by Drug Class Type
7.1.2.1 North America Targeted Therapy Market by Country
7.1.2.2 North America Immunotherapy (Biologic Therapy) Market by Country
7.1.2.3 North America Chemotherapy Market by Country
7.1.2.4 North America Hormonal Therapy Market by Country
7.1.3 North America Oncology Drugs Market by Country
7.1.3.1 US Oncology Drugs Market
7.1.3.1.1 US Oncology Drugs Market by Indication
7.1.3.1.2 US Oncology Drugs Market by Drug Class Type
7.1.3.2 Canada Oncology Drugs Market
7.1.3.2.1 Canada Oncology Drugs Market by Indication
7.1.3.2.2 Canada Oncology Drugs Market by Drug Class Type
7.1.3.3 Mexico Oncology Drugs Market
7.1.3.3.1 Mexico Oncology Drugs Market by Indication
7.1.3.3.2 Mexico Oncology Drugs Market by Drug Class Type
7.1.3.4 Rest of North America Oncology Drugs Market
7.1.3.4.1 Rest of North America Oncology Drugs Market by Indication
7.1.3.4.2 Rest of North America Oncology Drugs Market by Drug Class Type
7.2 Europe Oncology Drugs Market
7.2.1 Europe Oncology Drugs Market by Indication
7.2.1.1 Europe Breast Cancer Market by Country
7.2.1.2 Europe Prostate Cancer Market by Country
7.2.1.3 Europe Lung Cancer Market by Country
7.2.1.4 Europe Stomach Cancer Market by Country
7.2.1.5 Europe Colorectal Cancer Market by Country
7.2.1.6 Europe Liver Cancer Market by Country
7.2.1.7 Europe Esophagus Cancer Market by Country
7.2.1.8 Europe Cervical Cancer Market by Country
7.2.1.9 Europe Kidney Cancer Market by Country
7.2.1.10 Europe Bladder Cancer Market by Country
7.2.1.11 Europe Other Cancer Market by Country
7.2.2 Europe Oncology Drugs Market by Drug Class Type
7.2.2.1 Europe Targeted Therapy Market by Country
7.2.2.2 Europe Immunotherapy (Biologic Therapy) Market by Country
7.2.2.3 Europe Chemotherapy Market by Country
7.2.2.4 Europe Hormonal Therapy Market by Country
7.2.3 Europe Oncology Drugs Market by Country
7.2.3.1 Germany Oncology Drugs Market
7.2.3.1.1 Germany Oncology Drugs Market by Indication
7.2.3.1.2 Germany Oncology Drugs Market by Drug Class Type
7.2.3.2 UK Oncology Drugs Market
7.2.3.2.1 UK Oncology Drugs Market by Indication
7.2.3.2.2 UK Oncology Drugs Market by Drug Class Type
7.2.3.3 France Oncology Drugs Market
7.2.3.3.1 France Oncology Drugs Market by Indication
7.2.3.3.2 France Oncology Drugs Market by Drug Class Type
7.2.3.4 Russia Oncology Drugs Market
7.2.3.4.1 Russia Oncology Drugs Market by Indication
7.2.3.4.2 Russia Oncology Drugs Market by Drug Class Type
7.2.3.5 Spain Oncology Drugs Market
7.2.3.5.1 Spain Oncology Drugs Market by Indication
7.2.3.5.2 Spain Oncology Drugs Market by Drug Class Type
7.2.3.6 Italy Oncology Drugs Market
7.2.3.6.1 Italy Oncology Drugs Market by Indication
7.2.3.6.2 Italy Oncology Drugs Market by Drug Class Type
7.2.3.7 Rest of Europe Oncology Drugs Market
7.2.3.7.1 Rest of Europe Oncology Drugs Market by Indication
7.2.3.7.2 Rest of Europe Oncology Drugs Market by Drug Class Type
7.3 Asia Pacific Oncology Drugs Market
7.3.1 Asia Pacific Oncology Drugs Market by Indication
7.3.1.1 Asia Pacific Breast Cancer Market by Country
7.3.1.2 Asia Pacific Prostate Cancer Market by Country
7.3.1.3 Asia Pacific Lung Cancer Market by Country
7.3.1.4 Asia Pacific Stomach Cancer Market by Country
7.3.1.5 Asia Pacific Colorectal Cancer Market by Country
7.3.1.6 Asia Pacific Liver Cancer Market by Country
7.3.1.7 Asia Pacific Esophagus Cancer Market by Country
7.3.1.8 Asia Pacific Cervical Cancer Market by Country
7.3.1.9 Asia Pacific Kidney Cancer Market by Country
7.3.1.10 Asia Pacific Bladder Cancer Market by Country
7.3.1.11 Asia Pacific Other Cancer Market by Country
7.3.2 Asia Pacific Oncology Drugs Market by Drug Class Type
7.3.2.1 Asia Pacific Targeted Therapy Market by Country
7.3.2.2 Asia Pacific Immunotherapy (Biologic Therapy) Market by Country
7.3.2.3 Asia Pacific Chemotherapy Market by Country
7.3.2.4 Asia Pacific Hormonal Therapy Market by Country
7.3.3 Asia Pacific Oncology Drugs Market by Country
7.3.3.1 China Oncology Drugs Market
7.3.3.1.1 China Oncology Drugs Market by Indication
7.3.3.1.2 China Oncology Drugs Market by Drug Class Type
7.3.3.2 Japan Oncology Drugs Market
7.3.3.2.1 Japan Oncology Drugs Market by Indication
7.3.3.2.2 Japan Oncology Drugs Market by Drug Class Type
7.3.3.3 India Oncology Drugs Market
7.3.3.3.1 India Oncology Drugs Market by Indication
7.3.3.3.2 India Oncology Drugs Market by Drug Class Type
7.3.3.4 South Korea Oncology Drugs Market
7.3.3.4.1 South Korea Oncology Drugs Market by Indication
7.3.3.4.2 South Korea Oncology Drugs Market by Drug Class Type
7.3.3.5 Singapore Oncology Drugs Market
7.3.3.5.1 Singapore Oncology Drugs Market by Indication
7.3.3.5.2 Singapore Oncology Drugs Market by Drug Class Type
7.3.3.6 Malaysia Oncology Drugs Market
7.3.3.6.1 Malaysia Oncology Drugs Market by Indication
7.3.3.6.2 Malaysia Oncology Drugs Market by Drug Class Type
7.3.3.7 Rest of Asia Pacific Oncology Drugs Market
7.3.3.7.1 Rest of Asia Pacific Oncology Drugs Market by Indication
7.3.3.7.2 Rest of Asia Pacific Oncology Drugs Market by Drug Class Type
7.4 LAMEA Oncology Drugs Market
7.4.1 LAMEA Oncology Drugs Market by Indication
7.4.1.1 LAMEA Breast Cancer Market by Country
7.4.1.2 LAMEA Prostate Cancer Market by Country
7.4.1.3 LAMEA Lung Cancer Market by Country
7.4.1.4 LAMEA Stomach Cancer Market by Country
7.4.1.5 LAMEA Colorectal Cancer Market by Country
7.4.1.6 LAMEA Liver Cancer Market by Country
7.4.1.7 LAMEA Esophagus Cancer Market by Country
7.4.1.8 LAMEA Cervical Cancer Market by Country
7.4.1.9 LAMEA Kidney Cancer Market by Country
7.4.1.10 LAMEA Bladder Cancer Market by Country
7.4.1.11 LAMEA Other Cancer Market by Country
7.4.2 LAMEA Oncology Drugs Market by Drug Class Type
7.4.2.1 LAMEA Targeted Therapy Market by Country
7.4.2.2 LAMEA Immunotherapy (Biologic Therapy) Market by Country
7.4.2.3 LAMEA Chemotherapy Market by Country
7.4.2.4 LAMEA Hormonal Therapy Market by Country
7.4.3 LAMEA Oncology Drugs Market by Country
7.4.3.1 Brazil Oncology Drugs Market
7.4.3.1.1 Brazil Oncology Drugs Market by Indication
7.4.3.1.2 Brazil Oncology Drugs Market by Drug Class Type
7.4.3.2 Argentina Oncology Drugs Market
7.4.3.2.1 Argentina Oncology Drugs Market by Indication
7.4.3.2.2 Argentina Oncology Drugs Market by Drug Class Type
7.4.3.3 UAE Oncology Drugs Market
7.4.3.3.1 UAE Oncology Drugs Market by Indication
7.4.3.3.2 UAE Oncology Drugs Market by Drug Class Type
7.4.3.4 Saudi Arabia Oncology Drugs Market
7.4.3.4.1 Saudi Arabia Oncology Drugs Market by Indication
7.4.3.4.2 Saudi Arabia Oncology Drugs Market by Drug Class Type
7.4.3.5 South Africa Oncology Drugs Market
7.4.3.5.1 South Africa Oncology Drugs Market by Indication
7.4.3.5.2 South Africa Oncology Drugs Market by Drug Class Type
7.4.3.6 Nigeria Oncology Drugs Market
7.4.3.6.1 Nigeria Oncology Drugs Market by Indication
7.4.3.6.2 Nigeria Oncology Drugs Market by Drug Class Type
7.4.3.7 Rest of LAMEA Oncology Drugs Market
7.4.3.7.1 Rest of LAMEA Oncology Drugs Market by Indication
7.4.3.7.2 Rest of LAMEA Oncology Drugs Market by Drug Class Type
Chapter 8. Company Profiles
8.1 AbbVie, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 Amgen, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Acquisition and Mergers:
8.2.6 SWOT Analysis
8.3 Astellas Pharma, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.3.6 SWOT Analysis
8.4 AstraZeneca PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Product Launches and Product Expansions:
8.4.6 SWOT Analysis
8.5 Bristol Myers Squibb Company
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Product Launches and Product Expansions:
8.5.5.3 Acquisition and Mergers:
8.5.6 SWOT Analysis
8.6 F. Hoffmann-La Roche Ltd.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Product Launches and Product Expansions:
8.6.5.3 Acquisition and Mergers:
8.6.6 SWOT Analysis
8.7 Johnson & Johnson
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental & Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.7.5.2 Acquisition and Mergers:
8.7.6 SWOT Analysis
8.8 Novartis AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.8.6 SWOT Analysis
8.9 Merck & Co., Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.5.2 Acquisition and Mergers:
8.9.6 SWOT Analysis
8.10. Pfizer, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional & Segmental Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Partnerships, Collaborations, and Agreements:
8.10.6 SWOT Analysis
Chapter 9. Winning Imperatives of Oncology Drugs Market
Unique Offerings 
